Dieter Meier

Dieter Meier

Auto-generated profile, based on publicly available information

Dieter Meier

University and ETH Zurich

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1997 in Radiology
Verified
Journal Article
Closed access
RKR von Kummer
R von Kummer
KAK L Allen
K L Allen
RHR Holle
R Holle
LBL Bozzao
L Bozzao
SBStefano Bastianello
Stefano Bastianello
WHW Hacke
W Hacke
PURPOSE: To determine whether the extent of subtle parenchymal hypoattenuation detected on computed tomographic (CT) scans obtained within 6 hours of ischemic stroke is a factor in predicting patients' response to thrombolytic treatment. MATERIALS AND METHODS: The baseline CT scans of 620 patients, who received either recombinant tissue plasminogen activator (rt-PA) or a placebo, in a double-blind, randomized multicenter trial were prospectively evaluated and assigned to one of three categories according to the extent of parenchymal hypoattenuation: none, 33% or less (small), or more than 33% (large) of the middle cerebral artery territory. The association between the extent of hypoattenuation on the baseline CT scans and the clinical outcome in the placebo-treated and the rt-PA-treated groups after 3 months was analyzed. RESULTS: In 215 patients with a small hypoattenuating area, treatment increased the chance of good outcome. In 336 patients with a normal CT scan and in 52 patients with a large hypoatte...

1 December 1996 in Brain
Verified
Journal Article
Open access
PDF file
Angelo AntoniniAngelo Antonini
Angelo Antonini
KLK. L. Leenders
K. L. Leenders
RSR. Spiegel
R. Spiegel
DMD. Meier
D. Meier
PVP. Vontobel
P. Vontobel
RMR. P. Maguire
R. P. Maguire
We used PET scans with the tracers [18F]fluorodeoxyglucose (FDG) and [11C]raclopride (RACLO) to study glucose metabolism and dopamine D2 receptor binding in the caudate nucleus and putamen of 18 carriers of the Huntington's disease gene mutation (10 asymptomatic subjects and eight untreated symptomatic Huntington's disease patients in an early disease stage). We also performed MR1 scans and measured the bicaudate ratio (BCR) in the same subjects. Data were compared with those from nine mutation-negative members of Huntington's disease families and separate groups of age matched controls. The PET scans were repeated 1.5–3 years later in six of the asymptomatic gene carriers. Symptomatic Huntington's disease patients showed a marked reduction of FDG and RACLO uptake in the caudate nucleus and putamen and a significant increase of BCR. Asymptomatic mutation carriers revealed significant hypometabolism in the caudate nucleus and putamen. The RACLO binding was significantly decreased in the putamen. Decrements of caudate nucleus tracer uptake, particularly RACLO, correlated significantly with BCR increases in both symptomatic and asymptomatic gene carriers. In asymptomatic carriers, metabolic and receptor binding decreases were also significantly associated with the CAG repeat number but not with the individual's age. Discriminant function analysis correctly classified clinical and genetic status in 24 of 27 subjects on the basis of their striatal PET values (83% sensitivity and 100% specificity). Three asymptomatic mutation carriers were classified/grouped together with mutation-negative subjects, indicating that these individuals had normal striatal RACLO and FDG uptake. Follow-up PET data from gene-positive subjects showed a significant reduction in the mean striatal RACLO binding of 6.3% per year. Striatal glucose metabolism revealed an overall non significant 2.3% decrease per year These data indicate that asymptomatic Huntington's disease mutation carriers may show normal neuronal function for a long period of life. These findings also suggest that it may be possible to predict when an asymptomatic gene carrier will develop clinical symptoms from serial PET measurements of striatal function.

1 August 1998 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
XGXavier Golay
Xavier Golay
SKSpyros Kollias
Spyros Kollias
GSGautier Stoll
Gautier Stoll
DMDieter Meier
Dieter Meier
AVAnton Valavanis
Anton Valavanis
PBPeter Boesiger
Peter Boesiger

2 October 2001 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
UDUlrike Dydak
Ulrike Dydak
MWMarkus Weiger
Markus Weiger
KPKlaas P. Pruessmann
Klaas P. Pruessmann
DMDieter Meier
Dieter Meier
PBPeter Boesiger
Peter Boesiger
Sensitivity encoding (SENSE) offers a new, highly effective approach to reducing the acquisition time in spectroscopic imaging (SI). In contrast to conventional fast SI techniques, which accelerate k‐space sampling, this method permits reducing the number of phase encoding steps in each phase encoding dimension of conventional SI. Using a coil array for data acquisition, the missing encoding information is recovered exploiting knowledge of the distinct spatial sensitivities of the individual coil elements. In this work, SENSE is applied to 2D spectroscopic imaging. Fourfold reduction of scan time is achieved at preserved spectral and spatial resolution, maintaining a reasonable SNR. The basic properties of the proposed method are demonstrated by phantom experiments. The in vivo feasibility of SENSE‐SI is verified by metabolic imaging of N‐acetylaspartate, creatine, and choline in the human brain. These results are compared to conventional SI, with special attention to the spatial response and the SNR. Magn Reson Med 46:713–722, 2001.

1 February 2011 in Environmental Health Perspectives
Verified
Journal Article
Open access
Ulrike DydakUlrike Dydak
Ulrike Dydak
YJYue-Ming Jiang
Yue-Ming Jiang
LLLi-Ling Long
Li-Ling Long
HZHe Zhu
He Zhu
JCJian Chen
Jian Chen
WZWei Zheng
Wei Zheng
BackgroundExposure to excessive levels of manganese (Mn) is known to induce psychiatric and motor disorders, including parkinsonian symptoms. Therefore, finding a reliable means for early detection of Mn neurotoxicity is desirable.ObjectivesOur goal was to determine whether in vivo brain levels of γ-aminobutyric acid (GABA), N-acetylaspartate (NAA), and other brain metabolites in male smelters were altered as a consequence of Mn exposure.MethodsWe used T1-weighted magnetic resonance imaging (MRI) to visualize Mn deposition in the brain. Magnetic resonance spectroscopy (MRS) was used to quantify concentrations of NAA, glutamate, and other brain metabolites in globus pallidus, putamen, thalamus, and frontal cortex from a well-established cohort of 10 male Mn-exposed smelters and 10 male age-matched control subjects. We used the MEGA-PRESS MRS sequence to determine GABA levels in a region encompassing the thalamus and adjacent parts of the basal ganglia [GABA-VOI (volume of interest)].ResultsSeven of 10 expo...

1 April 1994 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
SFStefan E. Fischer
Stefan E. Fischer
GMGraeme C. McKinnon
Graeme C. McKinnon
MSMarkus B. Scheidegger
Markus B. Scheidegger
WPWim Prins
Wim Prins
DMDieter Meier
Dieter Meier
PBP. Boesiger
P. Boesiger